文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

减重手术后体重反弹的药物治疗管理。

Pharmacologic management of weight regain following bariatric surgery.

机构信息

Weill Cornell Medical Center, New York-Presbyterian, New York, NY, United States.

出版信息

Front Endocrinol (Lausanne). 2023 Jan 9;13:1043595. doi: 10.3389/fendo.2022.1043595. eCollection 2022.


DOI:10.3389/fendo.2022.1043595
PMID:36699042
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9868802/
Abstract

While bariatric surgery restults in significant long-term weight loss for most patients with obesity, post-surgical weight gain affects a considerable percentage of patients to varying degrees of severity. Furthermore, a small but significant percentage of patients experience inadequate post-surgical weight loss. Although many studies have examined the role of anti-obesity medications to address post-operative weight regain, an evidence-based consensus has not yet been achieved because of the heterogeneity of populations studied and the studies themselves. Observational studies in the post-bariatric surgery population consistently demonstrate the benefit of medical weight management after bariatric surgery, with most evidence highlighting liraglutide, topiramate, and phentermine/topiramate. New anti-obesity medications are anticipated to be helpful for post-surgical weight optimization given their efficacy in the non-surgical population.

摘要

虽然减重手术能使大多数肥胖患者长期显著减重,但术后体重增加会影响相当一部分患者,且严重程度不一。此外,还有一小部分患者术后减重不足。虽然许多研究已经探讨了抗肥胖药物在解决术后体重反弹中的作用,但由于研究人群和研究本身的异质性,尚未达成循证共识。减重手术后人群的观察性研究一致表明,减重手术后进行医学体重管理有益,其中大多数证据强调利拉鲁肽、托吡酯和 phentermine/topiramate。鉴于新的抗肥胖药物在非手术人群中的疗效,预计它们对术后体重优化有帮助。

相似文献

[1]
Pharmacologic management of weight regain following bariatric surgery.

Front Endocrinol (Lausanne). 2022

[2]
Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.

Obes Surg. 2024-5

[3]
Use of Weight Loss Medications in Patients after Bariatric Surgery.

Curr Obes Rep. 2021-6

[4]
Weight Loss Pharmacotherapy: Current and Future Therapies.

Gastrointest Endosc Clin N Am. 2024-10

[5]
The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.

Surg Obes Relat Dis. 2017-3

[6]
A Specialized Medical Management Program to Address Post-operative Weight Regain in Bariatric Patients.

Obes Surg. 2018-8

[7]
Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study.

Obes Surg. 2023-9

[8]
Efficacy of adjuvant weight loss medication after bariatric surgery.

Surg Obes Relat Dis. 2017-10-9

[9]
Pharmacological treatment of non-responders following bariatric surgery.

Minerva Endocrinol (Torino). 2024-6

[10]
Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain.

Expert Opin Pharmacother. 2019-3-18

引用本文的文献

[1]
Obesity Management Medications as Adjuncts to Metabolic and Bariatric Surgery: Consensus Recommendations from India.

Obes Surg. 2025-5-20

[2]
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.

Obes Surg. 2025-3

[3]
Ring Augmentation of the Roux-en-Y Gastric Bypass: A Propensity Score Matched Analysis of 5-Year Follow-Up Results.

Obes Surg. 2025-3

[4]
Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review.

Surg Obes Relat Dis. 2025-1

[5]
Challenges in the care and treatment of patients with extreme obesity.

Arch Endocrinol Metab. 2024

[6]
Weight Loss Pharmacotherapy: Current and Future Therapies.

Gastrointest Endosc Clin N Am. 2024-10

[7]
Semaglutide for weight loss: unanswered questions.

Front Endocrinol (Lausanne). 2024-6-5

[8]
Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings.

Obes Pillars. 2024-5-9

[9]
EndoBridge 2023: highlights and pearls.

Hormones (Athens). 2024-6

[10]
Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review.

Curr Obes Rep. 2024-6

本文引用的文献

[1]
Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med. 2022-7-21

[2]
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.

Nat Med. 2022-3

[3]
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

Lancet Diabetes Endocrinol. 2022-3

[4]
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

JAMA. 2022-1-11

[5]
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.

Aliment Pharmacol Ther. 2021-11

[6]
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.

Lancet Diabetes Endocrinol. 2021-9

[7]
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Lancet. 2021-7-10

[8]
Preoperative Weight Loss as a Predictor of Bariatric Surgery Postoperative Weight Loss and Complications.

J Gastrointest Surg. 2022-1

[9]
Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes.

Obesity (Silver Spring). 2021-5

[10]
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Lancet. 2021-3-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索